AI Technologies

“Safety Signals, Sooner: Audit-Ready Pharmacovigilance Narratives with RAG”

AE
a21.ai Editorial
December 16, 2025

Safety Narratives Are the Bottleneck Between Signals and Safety

The WHO defines pharmacovigilance as the science and activities related to detecting, assessing, understanding, and preventing adverse effects or any other medicine-related problems. (World Health Organization)

Yet the part that often slows everything down is the narrative.

    • Safety teams must turn individual case safety reports (ICSRs), lab values, medical histories, and literature into clear, consistent, medically sound stories.
    • Those narratives feed PSURs/PBRERs, signal evaluation, and responses to health authorities.
    • Every word has to be accurate, reproducible, and grounded in source evidence and company core data (SmPC, CCDS, RMP, internal guidance).

Manual narratives do get written—but they’re slow, vary by writer, and are hard to audit at scale.

Retrieval-augmented generation (RAG) offers a different way forward: let Generative AI write first drafts and summaries, but only using your approved safety sources, with every statement tied back to a document, section, and timestamp. Instead of “smart autocomplete,” you get safety narratives that can explain themselves.

This article looks at how pharmacovigilance teams can use RAG to:

    • Shorten narrative and aggregate-report cycle time
    • Improve consistency and medical completeness
    • Strengthen inspection readiness with traceable, audit-ready stories

We’ll stay focused on outcomes and governance—not model internals—so it’s usable for safety executives, not just data teams.

What RAG Really Means in Pharmacovigilance (Without the Jargon)



Most pharmacovigilance leaders have now heard “RAG” in AI discussions. But what does it actually do in your day-to-day PV operations?

At its core, RAG is a way to make Generative AI quote its sources.

Instead of letting a model “remember” everything, you:

    1. Store your trusted corpus – SmPCs/labels, CCDS, RMPs, SOPs, coding guidelines, past PSUR narratives, FAQs, signal assessments, and key regulatory references.
    1. Retrieve only what’s relevant – For a given case, query that corpus: product, MedDRA terms, time to onset, co-medications, special populations, similar prior cases, etc.
    1. Generate a narrative using only those retrieved documents – The AI drafts text, but injects citations to the exact paragraph, table, or prior case it’s pulling from.

If you want a more technical dive into how RAG architectures are evolving—and why “just plug your PDFs into a chatbot” isn’t enough—A21’s article “An Evolution of new RAG: The future of AI Search” breaks down the design choices behind modern RAG systems.
Read the evolution of RAG 

For pharmacovigilance, that means:

    • When the system says “This case is medically significant due to hospitalization and liver injury,” it can show you:

        • The case form with admission dates
        • The lab trends
        • The internal guidance that defines “medically significant”
    • When it mentions “known risk in the core data sheet,” it links to the CCDS section and label language it used.

In other words, RAG makes every narrative a story with receipts.

Where RAG Fits in the Pharmacovigilance Workflow

You don’t need a “big bang” transformation to get value. RAG fits into existing PV workflows in specific, high-friction steps:

1. Intake & Case Triage

    • Today: ICSRs arrive as E2B messages, emails, call notes, or portal submissions. Humans normalize fields, chase missing data, and tag seriousness and expectedness.
    • With RAG:

        • Multi-modal models read free-text and attachments, propose seriousness/relatedness hints, and highlight missing critical fields.
        • Retrieval pulls relevant label/CCDS wording and similar past cases so safety reviewers see context early.

Outcome: Cleaner, more complete cases hit medical review faster.

2. ICSR Narrative Drafting

    • Today: Writers stitch together multiple systems (safety database, EMR extracts, lab systems, email) to compose narratives that follow company templates.
    • With RAG:

        • The system ingests structured fields, free text, and attachments.
        • It retrieves relevant internal templates and coding guidance.
        • It drafts an ICSR narrative in your house style, with inline citations to source docs and fields.

Writers and medical reviewers still approve or edit—but they start from a grounded draft, not a blank page.

3. Line Listings and Aggregate Report Narratives

    • Today: Teams export line listings, manually group cases, and write sections like “Summary of serious hepatic events” or “Benefit–risk evaluation.”
    • With RAG:

        • Retrieval pulls the relevant case clusters, prior PSUR text, CCDS statements, and risk management commitments.
        • Generative AI drafts section text that:

            • Summarizes patterns (e.g., dose, time to onset, outcome)
            • Contrasts with background rates or prior periods
            • References the label or CCDS language that frames current knowledge

The result: aggregate narratives that are consistent across periods, linked to the underlying cases, and easier to defend.

4. Signal Evaluation & Regulatory Queries

    • Today: Responding to an authority query can mean weeks of pulling cases, re-summarizing, and aligning on exact wording.
    • With RAG:

        • Analysts define the cohort (e.g., all ICSRs for Drug X with MedDRA PTs related to cardiac events).
        • RAG retrieves those cases and related documents, then drafts a response structure: background, methods, observations, benefit–risk discussion.
        • Citations link to specific ICSRs, aggregate tables, and label sections.

You still refine wording and internal positions—but the heavy lifting of “read everything, summarize, cross-reference” is accelerated and made traceable.

From Alert Fatigue to “Explainable Narratives”: What Changes for Safety Teams

RAG doesn’t replace PV professionals—it changes the shape of their work.

    1. Less time on copy-paste, more time on judgment

        • Writers and reviewers start from drafts that already reflect core data and internal guidance, so they can focus on medical nuance, not formatting or hunting for phrasing.
    1. Fewer versioning and consistency headaches

        • Narratives pull from the same central repository; when CCDS or label text updates, new drafts automatically reflect it.
        • This reduces the risk of outdated language creeping into ICSRs or periodic reports.
    1. Clearer inspection trail

        • Health authorities and inspectors increasingly expect transparent methods and traceable reasoning—especially as AI enters the picture.
        • A RAG pipeline that stores “question → documents retrieved → draft → human edits” gives QA, PV QPPV, and inspectors a full replay of how text was produced.

Industry analyses on real-world evidence and analytics in pharma highlight how advanced analytics in safety and RWE are becoming a competitive and compliance differentiator, not a “nice to have.” (McKinsey & Company) RAG is one of the practical mechanisms that lets you operationalize that analytics layer into everyday PV work.

Making RAG Safe for Pharmacovigilance: Governance by Design



Because pharmacovigilance sits under heavy regulatory scrutiny, RAG must be deployed with governance built in, not bolted on. A few non-negotiables:

1. Defined Corpora and Access Controls

    • Limit RAG to approved, versioned sources: labels, CCDS, RMPs, SOPs, QMS documents, prior validated narratives, and regulatory guidelines.
    • Tag content by product, indication, region, and sensitivity (e.g., internal assessments vs. externally approved text).
    • Enforce role-based access; for example, internal risk assessments may feed internal narratives but never patient-facing materials.

2. Human-in-the-Loop Everywhere it Matters

    • Treat AI-generated content as drafts only; SOPs should mandate human review and sign-off for:

        • ICSRs
        • PSUR/PBRER sections
        • Safety signal assessments
        • Responses to health authorities
    • Capture “who approved what, when” alongside the AI trace for full accountability.

A21’s RAG(e) Deployment playbook goes deeper into designing RAG systems with strong guardrails, evaluations, and change control—so safety teams aren’t left with a black box to defend.
Explore the RAG(e) deployment approach 

3. Evaluation and Monitoring, Not Blind Trust

    • Build a small evaluation set of historical cases and reports where “gold standard” narratives and conclusions exist.
    • Regularly test RAG outputs for:

        • Factual alignment with source data
        • Citation quality (does each claim have an appropriate source?)
        • Medical completeness (key clinical elements present)
    • Monitor for drift whenever you change models, corpora, or chunking strategies.

4. Documentation for Inspectors

    • Document, in plain language:

        • What RAG is allowed to do (e.g., draft narratives, never auto-submit)
        • Which corpora it can use
        • How human review is enforced
        • How logs can be exported for inspection

This turns AI from a risk to explain away into a tool you can proactively show regulators as evidence of improved consistency and traceability.

Quantifying the Impact: Time, Quality, and Inspection Readiness

To build a business case, tie RAG to metrics PV leaders already track.

Cycle Time & Capacity

    • Baseline: average writer/reviewer hours per ICSR and per PSUR/PBRER.
    • With RAG: teams commonly target:

        • 30–40% reduction in time spent on first-pass narrative drafting
        • Faster turnaround on periodic reports thanks to reusable, grounded sections

Even modest gains—e.g., 20% fewer hours on narrative work—free significant time in high-volume portfolios.

Consistency & Rework

    • Track:

        • Narrative rework rate after medical review
        • Findings from internal QA (e.g., missing data elements, inconsistent references to label or CCDS)
    • With grounded drafts from a single corpus, you should see:

        • Fewer “style” edits
        • Reduced discrepancies between what’s written and what’s in the safety database or CCDS

Inspection & Audit Readiness

    • Baseline: time spent assembling documentation for inspections or addressing follow-up questions about specific cases or sections.
    • With RAG logs and citations, you can:

        • Show exactly which documents supported each phrase
        • Reconstruct earlier drafts without manual email digging
        • Reduce the effort needed to answer “Why did you write it that way?”

Collectively, these improvements move pharmacovigilance from reactive firefighting to proactive, analytics-driven operations—while keeping patient safety and regulatory compliance at the center.

A 90-Day Plan to Pilot RAG in Pharmacovigilance Narratives

You don’t need to transform the entire safety organization at once. A focused 90-day pilot can prove value and de-risk scale-up.

Days 0–30: Choose a Narrow, High-Volume Use Case

    • Pick one product/indication and one narrative type (e.g., non-serious ICSRs for a mature product, or a specific PSUR section).
    • Define success metrics: hours saved, reduction in rework, improved completeness.
    • Stand up a small RAG corpus: label, CCDS, coding rules, and a sample of prior narratives.

Days 31–60: Put Writers and Reviewers in the Loop

    • Integrate RAG drafting into existing authoring tools or workflows.
    • Have writers compare: manual vs. RAG-assisted.
    • Collect structured feedback: where drafts were helpful, where they missed clinical nuance, where citations were weak.

Days 61–90: Harden Guardrails and Prepare for Inspection Questions

    • Refine corpora and templates based on feedback.
    • Implement SOP updates covering human review, documentation, and log retention.
    • Prepare a short, inspector-friendly explainer of how RAG is used and governed.

By the end of 90 days, you should be able to show:

    • Concrete time and quality improvements
    • A clear governance model
    • A roadmap for extending RAG to other products and safety documents

Way Forward

If you want safety signals to surface sooner and pharmacovigilance narratives that explain themselves, RAG is one of the most practical levers you can pull.

A21 works with life-sciences teams to design and deploy retrieval-grounded safety workflows—from ICSR narratives to aggregate reports and signal responses—built to pass both internal QA and regulator scrutiny.

Click to read our blog and explore how audit-ready RAG can fit into your pharmacovigilance roadmap.

Learn more !

Get on a 1:1 call with our experts to discuss how Generative AI can add value to your organization !

Book a Call →
Pharma